폐암 (NSCLC)

5개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#monoclonal-antibody#BeiGene
Trials 4Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 2

atezolizumab (Tecentriq, Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab)

Extensive Stage Lung Small Cell Cancer · Extensive Stage Lung Small Cell Cancer

#ExtensiveStageLungSmallCellCance#Antibody#Phase2#monoclonal-antibody#BeiGene
Trials 2Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
AntibodyLimited DatastaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#Non-squamousNon-smallCellLungCan+2
Trials 1Status Active